In the past week, CAPR stock has gone down by -5.02%, with a monthly gain of 10.28% and a quarterly surge of 407.71%. The volatility ratio for the week is 7.73%, and the volatility levels for the last 30 days are 11.39% for Capricor Therapeutics Inc The simple moving average for the last 20 days is -4.70% for CAPR stock, with a simple moving average of 166.86% for the last 200 days.
Is It Worth Investing in Capricor Therapeutics Inc (NASDAQ: CAPR) Right Now?
The stock has a 36-month beta value of 4.04. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CAPR is 37.83M, and at present, short sellers hold a 16.34% of that float. On November 07, 2024, the average trading volume of CAPR was 2.98M shares.
CAPR) stock’s latest price update
Capricor Therapeutics Inc (NASDAQ: CAPR)’s stock price has plunge by 4.72relation to previous closing price of 18.23. Nevertheless, the company has seen a -5.02% plunge in its stock price over the last five trading sessions. zacks.com reported 2024-11-07 that Here is how Capricor Therapeutics (CAPR) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Piper Sandler repeating the rating for CAPR by listing it as a “Overweight.” The predicted price for CAPR in the upcoming period, according to Piper Sandler is $35 based on the research report published on October 21, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $14. The rating they have provided for CAPR stocks is “Outperform” according to the report published on May 17th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to CAPR, setting the target price at $8 in the report published on January 05th of the current year.
CAPR Trading at 41.26% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.42% of loss for the given period.
Volatility was left at 11.39%, however, over the last 30 days, the volatility rate increased by 7.73%, as shares surge +10.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +303.41% upper at present.
During the last 5 trading sessions, CAPR fell by -5.87%, which changed the moving average for the period of 200-days by +363.73% in comparison to the 20-day moving average, which settled at $20.02. In addition, Capricor Therapeutics Inc saw 290.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -1.1 for the present operating margin
- 0.95 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -1.03. The total capital return value is set at -1.87. Equity return is now at value -392.69, with -66.31 for asset returns.
Based on Capricor Therapeutics Inc (CAPR), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -8.14. The debt to equity ratio resting at 0.36. The interest coverage ratio of the stock is 0.07.
Currently, EBITDA for the company is -23.01 million with net debt to EBITDA at 0.19. When we switch over and look at the enterprise to sales, we see a ratio of 32.12. The receivables turnover for the company is 73.39for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
To sum up, Capricor Therapeutics Inc (CAPR) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
